Back to search

University of Patras

Ο ρόλος της τροποποιημένης μεγίστης θυμεκτομής στην έκβαση των ασθενών με βαρεία μυασθένεια

Abstract

dc:description

Objective: Thymectomy represents a widely accepted treatment for myasthenia gravis with different surgical approaches reported as comparably efficient in achieving disease's remission. With the complete stable remission being currently accepted as a clear measurable outcome of patients with myasthenia undergoing surgical treatment and the knowledge that disease's remission should be evaluated as a time dependent event we proceeded to a retrospective analysis of our experience on the surgical management of myasthenic patients. The objective was to access the effect of maximal resection on the neurological outcome and identify predictors of disease remission. Materials and methods: The study group consisted of 78 patients who underwent modified maximal thymectomy for myasthenia from 1990 to 2007 Indications for thymectomy included ocular myasthenia refractory to medical treatment generalized myasthenia and thymomatous myasthenia. The data collected included preoperative disease's severity (modified Osserman classification), preoperative medical treatment, age at onset of the disease (< 40 / > 40 years), time elapsed between diagnosis and thymectomy (< 12 / > 12 months), gender, thymus gland histology, mortality and morbidity In thymoma patients further analysis was carried out according the World Health Organization histological classification and the Masaoka stage of the tumors. The evaluation of the neurological outcome at the end of follow up was performed according the Myasthenia Gravis Foundation of America classification. Both the effectiveness of the resection performed and the comparison of our results with those of previous studies were done using the complete stable remission as the end point of the study. The statistical analysis of the results was carried out using the SPSS 17 Kaplan-Meier life table analysis was performed and the log rank test was used to evaluate the effect of the variables examined on the distribution of disease's remission over time. The Cox proportional hazard model was also applied to verify the concurrent effect of the evaluated factors on the achievement of complete stable remission Ρ values < 0.05 were considered statistically significant. Results: 51 patients suffered of non thymomatous myasthenia while 27 patients had myasthenia with thymoma. The two groups were comparable in refer to the clinical features of the patients apart the more advanced age at the time of the diagnosis for thymoma patients. There was no perioperative mortality, while the surgical morbidity was comparable to the one reported in other series of patients with different surgical approaches and was 7.7%. The rate of postoperative myasthenic crisis was only 3.8%. Thymoma and non thymoma patients experienced comparable complete stable remission prediction (74.5% vs 85.7% at 15 years, p= 0.632). The absence of steroids in the preoperative medical regimen was statistically associated with the achievement of complete stable remission in both thymoma (95% CI 2.687-339.182, p= 0.006) and non thymoma patients (CI 95% 1.607-19.183, P= 0.007) in multivariate analysis. There was an important difference, although not statistically significant, for the neurological outcome between early and late surgical treatment. When the 27 patients with myasthenia and thymoma were compared with other 12 patients similarly operated for thymoma without symptoms and signs of muscular weakness we found that the presence of myasthenia was statistically associated with improved survival (100% vs 38.8% at 10 years, p< 0. 001). Non thymoma patients presenting with late onset myasthenia, experienced high improvement (complete stable remission excluded) rate reaching up to 70% at the end of follow up. Among patients with thymomatous myasthenia gravis the World Health Organization histological classification was statistically associated with the late neurological outcome. Thymoma types A, B3 and B2 reached a high to excellent prediction of disease's remission while types AB, B2 and C had a disappointing neurological outcome. Conclusions: The present study demonstrated that the modified maximal thymectomy is a safe procedure, associated with an excellent neurological outcome in both thymomatous and non thymomatous myasthenia. The patients should be operated early after the diagnosis is made with the disease's severity being the prime determinant of the possibility to achieve complete remission of myasthenic symptoms. The evaluation of disease's severity requires objective criteria like the ones proposed by the Myasthenia Gravis Foundation of America. The inclusion in these criteria of molecular markers related to myasthenia's prognosis and its neurological outcome after thymectomy may further enhance its validity and may allow the identification of subgroups of patients with different disease prognosis after thymectomy. The presence of muscular weakness may lead to early diagnosis and surgical treatment of thymomas with improved survival. Finally the neurologic outcome in thymoma patients after thymectomy may be statistically associated with the World Health Organization classification subtypes but not necessarily with the aggressiveness of these tumors.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Prokakis, Christos
  • Προκάκης, Χρήστος

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/22950

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Prokakis, Christos; Προκάκης, Χρήστος. Ο ρόλος της τροποποιημένης μεγίστης θυμεκτομής στην έκβαση των ασθενών με βαρεία μυασθένεια. University of Patras, 2010. http://hdl.handle.net/10442/hedi/22950